Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

BDSX vs NTRA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BDSX
Biodesix, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$117M
5Y Perf.-93.8%
NTRA
Natera, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$31.16B
5Y Perf.+188.8%

BDSX vs NTRA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BDSX logoBDSX
NTRA logoNTRA
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$117M$31.16B
Revenue (TTM)$96M$2.31B
Net Income (TTM)$-32M$-208M
Gross Margin59.9%64.8%
Operating Margin-26.0%-13.4%
Total Debt$73M$214M
Cash & Equiv.$19M$1.08B

BDSX vs NTRALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BDSX
NTRA
StockOct 20May 26Return
Biodesix, Inc. (BDSX)1006.2-93.8%
Natera, Inc. (NTRA)100288.8+188.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: BDSX vs NTRA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NTRA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Biodesix, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BDSX
Biodesix, Inc.
The Income Pick

BDSX is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 0.25
  • Lower volatility, beta 0.25, current ratio 1.86x
  • Beta 0.25, current ratio 1.86x
Best for: income & stability and sleep-well-at-night
NTRA
Natera, Inc.
The Growth Play

NTRA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
  • 20.9% 10Y total return vs BDSX's -94.0%
  • 35.9% revenue growth vs BDSX's 24.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNTRA logoNTRA35.9% revenue growth vs BDSX's 24.1%
Quality / MarginsNTRA logoNTRA-9.0% margin vs BDSX's -33.3%
Stability / SafetyBDSX logoBDSXBeta 0.25 vs NTRA's 1.26
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)BDSX logoBDSX+82.6% vs NTRA's +37.3%
Efficiency (ROA)NTRA logoNTRA-10.6% ROA vs BDSX's -35.6%, ROIC -36.1% vs -38.7%

BDSX vs NTRA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BDSXBiodesix, Inc.
FY 2025
Diagnostic Tests
89.5%$79M
Development Services
10.5%$9M
NTRANatera, Inc.
FY 2025
Product
99.6%$2.3B
Licensing and other
0.4%$10M

BDSX vs NTRA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNTRALAGGINGBDSX

Income & Cash Flow (Last 12 Months)

NTRA leads this category, winning 5 of 6 comparable metrics.

NTRA is the larger business by revenue, generating $2.3B annually — 24.0x BDSX's $96M. NTRA is the more profitable business, keeping -9.0% of every revenue dollar as net income compared to BDSX's -33.3%.

MetricBDSX logoBDSXBiodesix, Inc.NTRA logoNTRANatera, Inc.
RevenueTrailing 12 months$96M$2.3B
EBITDAEarnings before interest/tax-$21M-$310M
Net IncomeAfter-tax profit-$32M-$208M
Free Cash FlowCash after capex-$25M$97M
Gross MarginGross profit ÷ Revenue+59.9%+64.8%
Operating MarginEBIT ÷ Revenue-26.0%-13.4%
Net MarginNet income ÷ Revenue-33.3%-9.0%
FCF MarginFCF ÷ Revenue-26.3%+4.2%
Rev. Growth (YoY)Latest quarter vs prior year+42.3%+39.8%
EPS Growth (YoY)Latest quarter vs prior year+49.4%+185.4%
NTRA leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — BDSX and NTRA each lead in 1 of 2 comparable metrics.
MetricBDSX logoBDSXBiodesix, Inc.NTRA logoNTRANatera, Inc.
Market CapShares × price$117M$31.2B
Enterprise ValueMkt cap + debt − cash$171M$30.3B
Trailing P/EPrice ÷ TTM EPS-3.31x-144.62x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue1.32x13.51x
Price / BookPrice ÷ Book value/share17.55x
Price / FCFMarket cap ÷ FCF285.53x
Evenly matched — BDSX and NTRA each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

NTRA leads this category, winning 6 of 8 comparable metrics.

NTRA delivers a -15.3% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-21 for BDSX. On the Piotroski fundamental quality scale (0–9), NTRA scores 5/9 vs BDSX's 3/9, reflecting solid financial health.

MetricBDSX logoBDSXBiodesix, Inc.NTRA logoNTRANatera, Inc.
ROE (TTM)Return on equity-21.0%-15.3%
ROA (TTM)Return on assets-35.6%-10.6%
ROICReturn on invested capital-38.7%-36.1%
ROCEReturn on capital employed-36.4%-18.3%
Piotroski ScoreFundamental quality 0–935
Debt / EquityFinancial leverage0.13x
Net DebtTotal debt minus cash$54M-$862M
Cash & Equiv.Liquid assets$19M$1.1B
Total DebtShort + long-term debt$73M$214M
Interest CoverageEBIT ÷ Interest expense-4.47x-25.21x
NTRA leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

NTRA leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $543 for BDSX. Over the past 12 months, BDSX leads with a +82.6% total return vs NTRA's +37.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs BDSX's -21.8% — a key indicator of consistent wealth creation.

MetricBDSX logoBDSXBiodesix, Inc.NTRA logoNTRANatera, Inc.
YTD ReturnYear-to-date+139.5%-3.9%
1-Year ReturnPast 12 months+82.6%+37.3%
3-Year ReturnCumulative with dividends-52.3%+314.0%
5-Year ReturnCumulative with dividends-94.6%+115.9%
10-Year ReturnCumulative with dividends-94.0%+2089.4%
CAGR (3Y)Annualised 3-year return-21.8%+60.6%
NTRA leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BDSX and NTRA each lead in 1 of 2 comparable metrics.

BDSX is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NTRA currently trades 85.7% from its 52-week high vs BDSX's 76.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBDSX logoBDSXBiodesix, Inc.NTRA logoNTRANatera, Inc.
Beta (5Y)Sensitivity to S&P 5000.40x1.17x
52-Week HighHighest price in past year$20.11$256.36
52-Week LowLowest price in past year$3.44$131.81
% of 52W HighCurrent price vs 52-week peak+76.9%+85.7%
RSI (14)Momentum oscillator 0–10062.557.1
Avg Volume (50D)Average daily shares traded103K1.3M
Evenly matched — BDSX and NTRA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates BDSX as "Buy" and NTRA as "Buy". Consensus price targets imply 20.8% upside for NTRA (target: $266) vs -44.0% for BDSX (target: $9).

MetricBDSX logoBDSXBiodesix, Inc.NTRA logoNTRANatera, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$8.67$265.63
# AnalystsCovering analysts727
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

NTRA leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallNatera, Inc. (NTRA)Leads 3 of 6 categories
Loading custom metrics...

BDSX vs NTRA: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is BDSX or NTRA a better buy right now?

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 24. 1% for Biodesix, Inc. (BDSX). Analysts rate Biodesix, Inc. (BDSX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — BDSX or NTRA?

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -94. 6% for Biodesix, Inc. (BDSX). Over 10 years, the gap is even starker: NTRA returned +1835% versus BDSX's -94. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — BDSX or NTRA?

By beta (market sensitivity over 5 years), Biodesix, Inc.

(BDSX) is the lower-risk stock at 0. 40β versus Natera, Inc. 's 1. 17β — meaning NTRA is approximately 190% more volatile than BDSX relative to the S&P 500.

04

Which is growing faster — BDSX or NTRA?

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 24. 1% for Biodesix, Inc. (BDSX). On earnings-per-share growth, the picture is similar: Biodesix, Inc. grew EPS 29. 2% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — BDSX or NTRA?

Natera, Inc.

(NTRA) is the more profitable company, earning -9. 0% net margin versus -39. 8% for Biodesix, Inc. — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 4% versus -31. 5% for BDSX. At the gross margin level — before operating expenses — BDSX leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — BDSX or NTRA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is BDSX or NTRA better for a retirement portfolio?

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), +1835% 10Y return). Both have compounded well over 10 years (NTRA: +1835%, BDSX: -94. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between BDSX and NTRA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

BDSX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 21%
  • Gross Margin > 35%
Run This Screen
Stocks Like

NTRA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 38%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BDSX and NTRA on the metrics below

Revenue Growth>
%
(BDSX: 42.3% · NTRA: 39.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.